pemigatinib
specialised therapeutics,incyte
 fight-101, a first-in-human study of potent and selective fgfr 1-3 inhibitor pemigatinib in pan-cancer patients with fgf/fgfr alterations ( fusions, rearragements, mutations &amp; amplifications) #precisionmedicine 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.